J Alzheimer dis: low dose of methionine can effectively alleviate cognitive decline

December 3, 2019 / BIOON / -- in a recent paper published in Journal of Alzheimer's disease, taurx reported the results of pharmacokinetic analysis In this study, we analyzed the relationship between the therapeutic dose, blood level and the pharmacological activity of methionine on the brain in more than 1000 patients with mild cirrhosis These results suggest that even at the lowest dose (8 mg / day) previously tested in two phase III global trials, the drug has a concentration dependent therapeutic effect on cognitive decline and brain atrophy Hmmet is a generic name for a compound previously known as lmtm approved by who The drug can block the abnormal accumulation of tau protein in the brain, which has been increasingly considered as an important driver of clinical dementia In the three phase global clinical trials between 2012 and 2012, the study conducted a dose test of 150-250 mg / day and a low dose test of 8 mg / day for 1700 patients with mild to moderate Alzheimer's disease Surprisingly, there was no difference between high and low doses of HMS in any of the clinical results of the trial To further explore these results, the researchers used plasma concentration data from 1162 patients who participated in either of the two completed phase 3 hmmet trials to perform a new pharmacokinetic population analysis to measure how the blood levels of the drug correlated with their effects on the brain Using a new assay, the researchers found that the effect of methionine at a dose of 8 mg / day was determined by the blood concentration, and that most patients had a sufficiently high blood concentration at that dose, leading to a significant reduction in cognitive ability Recession and brain atrophy They concluded that a slightly higher dose of hmet was 16 mg / day, which would ensure that all patients had the blood levels needed to maximize the activity of the drug, as its effect would be stable at higher concentrations and doses They found that many drugs have typical pharmacokinetic characteristics, which can now explain why the pharmacological effects of the high-dose hmmet tested in the trial are not superior to those seen in the 8 mg / day dose of hyperlipidemia patients The analysis also showed that although hmmet had a similar concentration response curve in patients taking the drug as an adjunct to ad's routine use of symptomatic treatment, the maximum efficacy of these patients was reduced by half This finding supports the hypothesis that the symptomatic drugs against this condition will interfere with the therapeutic effect of hmmet on improving the disease "Because we already have an important database to support the safety and tolerability of methionine in clinical trials in patients with mild to moderate Alzheimer's disease This trial confirmed the potential efficacy of 16 mg / day of HMT in these types of patients, "said Professor caude wischik and executive chairman of taurx therapeutics Ltd, University of Aberdeen He pointed out that hmmet, which is taken in a convenient oral form at home, does not require patients to go to the clinic for intravenous infusion or injection, unlike various other Alzheimer's treatment methods currently being tested in clinical trials Professor George Perry, editor in chief of the Journal of Alzheimer's disease, commented: "extensive data, experience and current pharmacokinetics highlight the potential of hmmet as an important new approach to Alzheimer's disease." Sources of information: hydromethionine could slow cognitive decline: minimum dose, Bjoern o schelter, Helen Shiells, Thomas C Baddeley, Christopher M Rubino, Harish Ganesan, Jeffrey Hammel, vesna vuksanovic, Roger T staff, Alison D Murray, Luc bracoud, Gernot Riedel, Serge Gauthier, Jianping Jia, Peter Bentham, Karin kook, John M.D Storey, Charles R Harrington, Claude M Wischik Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease Journal of Alzheimer's Disease , 2019; 72 (3): 931 DOI: 10.3233/JAD-190772